



Press release

SHL announces invitation to a Special General Meeting

Tel Aviv / Zurich August 28, 2018 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that a Special General Meeting of the Shareholders will be held on **October 18, 2018** at 13:00 p.m. (Israel Time), at the Company’s registered office, located at 90 Yigal Alon Street, Ashdar Building, Tel-Aviv, Israel. The agenda shall include the following matters:

1. Election of one (1) Independent (External) Director to the Board of Directors of the Company, pursuant to Section 239(b) of the Israeli Companies Law, 1999 (the “Companies Law”), for a three (3) year term.

The Independent (external) director nominees have submitted to the Company the declarations required pursuant to Sections 224b, 241(a) of the Companies Law with respect to fulfilling the legal requirements to serve as Independent (external) Director of the Company.

The names of the candidates, by alphabetical order, are: (1) Ms. Ruth Gal; (2) Ms. Dvorah Kimhi; (3) Ms. Nomi Sandhaus; and (4) Ms. Eti Vidavsky.

2. Following recommendation and approval by the Company’s Compensation Committee and Board – grant of 18,000 options to Ms. Shechter who was appointed as a Director in May 2018;
3. Following recommendation and approval by the Company’s Compensation Committee and Board - approval of an annual bonus for the year 2017 to the Company’s Chief Executive Officer;
4. Following recommendation and approval by the Company’s Compensation Committee and Board - approval of the payment of a one-time reduced special retirement bonus to the Company’s former Chief Executive Officer;

All of the above as more fully set forth in the Notice to Shareholders available on the Company’s website.

The record date was set for **October 11, 2018**.

One or more shareholders holding at least one percent (1%) of the voting rights at the Special General Meeting may request the Board to add an item to the agenda to the extent such is fit to be discussed thereat. Such request shall be made no later than seven (7) days from the invitation to the Special General Meeting (i.e. **September 4, 2018**). A request to include a proposed candidate for a director, shall include the details set forth under Section 26 of the Securities Regulations (Periodical and Immediate Reports) – 1970, as well as the declaration of such candidate pursuant to Section 224B of the Companies Law and pursuant to Section 241 of the Companies Law. The Company will publish an updated agenda and ballot (in the event items and names of candidates are added per a shareholder’s request), not later than on **September 12, 2018** on the Company’s website at <http://www.shl-telemedicine.com/about-us/investorrelations/general-meeting/>.



The invitation to the SGM shall not be published in newspapers. The full invitation to the SGM can be downloaded on <http://www.shl-telemedicine.com/about-us/investorrelations/general-meeting/>. The background material is available on the website or in the Company's offices, or will be forwarded upon request, all as indicated in the Notice to Shareholders.

For further information, please contact:

Martin Meier-Pfister, IRF Communications, phone : +41 43 244 81 40, shl@irfcom.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call centre services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957). For more information, please visit the web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.